BACKGROUND: Life-threatening infections are a major cause of death after allogeneic stem cell transplantation. Complement Mannose-binding lectin is a key component of innate immunity. Functional deficiency of mannose-binding lectin due to genetic polymorphism is frequent. Previous reports showed conflicting results with respect to the influence of functional mannose-binding lectin deficiency on infectious risk after allogeneic stem cell transplantation. The aim of this study was to clarify the impact of low mannose-binding lectin levels on infectious risk in a unique cohort of very long-term survivors after stem cell transplantation. DESIGN AND METHODS: Incidence of major infections was evaluable in 43 out of 44 very long-term survivors (over ten years) and studied retrospectively in relation to mannose-binding lectin serum concentrations. RESULTS: Recipients with mannose-binding lectin levels below 1,000 ng/mL were at increased risk to suffer from one or more major infections (P=0.002) during entire follow up. Infectious susceptibility was increased after neutrophil recovery, particularly until 24 months (Hazard Ratio 3.4) with sustained effects afterwards (Hazard Ratio 2.9). Mannose-binding lectin serum concentrations below 1,000 ng/mL were independently associated with major infections after neutrophil recovery (P=0.009). In subgroup analyses occurrence of severe herpes virus infections in particular was associated with significantly lower mannose-binding lectin levels (P=0.02). CONCLUSIONS: Our findings indicate that low mannose-binding lectin levels may predict markedly increased susceptibility to severe infections with sustained effects even late after allogeneic stem cell transplantation. Determinations of mannose-binding lectin status should therefore be included into pre-transplantation risk assessment.
BACKGROUND: Life-threatening infections are a major cause of death after allogeneic stem cell transplantation. Complement Mannose-binding lectin is a key component of innate immunity. Functional deficiency of mannose-binding lectin due to genetic polymorphism is frequent. Previous reports showed conflicting results with respect to the influence of functional mannose-binding lectin deficiency on infectious risk after allogeneic stem cell transplantation. The aim of this study was to clarify the impact of low mannose-binding lectin levels on infectious risk in a unique cohort of very long-term survivors after stem cell transplantation. DESIGN AND METHODS: Incidence of major infections was evaluable in 43 out of 44 very long-term survivors (over ten years) and studied retrospectively in relation to mannose-binding lectin serum concentrations. RESULTS: Recipients with mannose-binding lectin levels below 1,000 ng/mL were at increased risk to suffer from one or more major infections (P=0.002) during entire follow up. Infectious susceptibility was increased after neutrophil recovery, particularly until 24 months (Hazard Ratio 3.4) with sustained effects afterwards (Hazard Ratio 2.9). Mannose-binding lectin serum concentrations below 1,000 ng/mL were independently associated with major infections after neutrophil recovery (P=0.009). In subgroup analyses occurrence of severe herpes virus infections in particular was associated with significantly lower mannose-binding lectin levels (P=0.02). CONCLUSIONS: Our findings indicate that low mannose-binding lectin levels may predict markedly increased susceptibility to severe infections with sustained effects even late after allogeneic stem cell transplantation. Determinations of mannose-binding lectin status should therefore be included into pre-transplantation risk assessment.
Authors: G Socié; J V Stone; J R Wingard; D Weisdorf; P J Henslee-Downey; C Bredeson; J Y Cahn; J R Passweg; P A Rowlings; H C Schouten; H J Kolb; J P Klein Journal: N Engl J Med Date: 1999-07-01 Impact factor: 91.245
Authors: Katy J Fidler; Peter Wilson; Jane C Davies; Malcolm W Turner; Mark J Peters; Nigel J Klein Journal: Intensive Care Med Date: 2004-05-04 Impact factor: 17.440
Authors: Anja Roos; Peter Garred; Manon E Wildenberg; Nicholas J Lynch; Jeric R Munoz; Tahlita C M Zuiverloon; Lee H Bouwman; Nicole Schlagwein; Francien C Fallaux van den Houten; Maria C Faber-Krol; Hans O Madsen; Wilhelm J Schwaeble; Misao Matsushita; Teizo Fujita; Mohamed R Daha Journal: Eur J Immunol Date: 2004-09 Impact factor: 5.532
Authors: D C Kilpatrick; K Stewart; E K Allan; L A McLintock; T L Holyoake; M L Turner Journal: Bone Marrow Transplant Date: 2005-01 Impact factor: 5.483
Authors: M M Riwes; H Leather; D Neal; C Bennett; M Sugrue; C Cline; J Stokes; J Hiemenz; J Hsu; J R Wingard Journal: Bone Marrow Transplant Date: 2016-04-18 Impact factor: 5.483
Authors: M Puente; C Fariñas-Alvarez; A Moreto; P Sánchez-Velasco; J G Ocejo-Vinyals; M C Fariñas Journal: BMC Immunol Date: 2019-11-09 Impact factor: 3.615
Authors: Severin Vogt; Jörg D Leuppi; Jonas Rutishauser; Michael Osthoff; Philipp Schuetz; Beat Mueller; Carmen Volken; Sarah Dräger; Marten Trendelenburg Journal: Respir Res Date: 2021-08-14
Authors: Adrian Egli; Juliane Schäfer; Michael Osthoff; Steffen Thiel; Christina Mikkelsen; Andri Rauch; Hans H Hirsch; Heiner C Bucher; James Young; Jens C Jensenius; Manuel Battegay; Marten Trendelenburg Journal: PLoS One Date: 2013-01-04 Impact factor: 3.240
Authors: Ana Moreto; Concepción Fariñas-Alvarez; Maria Puente; Javier Gonzalo Ocejo-Vinyals; Pablo Sánchez-Velasco; Juan Pablo Horcajada; Ana Batlle; Carmen Montes; Francisca Santos; Eulogio Conde; Maria-Carmen Fariñas Journal: BMC Immunol Date: 2014-05-03 Impact factor: 3.615